Clinical Trials
Several clinical trials evaluate Rhamnose as a probe to assess intestinal barrier function, carbohydrate absorption, and mucosal permeability across conditions including increased intestinal permeability, metabolic disturbances, ulcerative colitis, environmental enteropathy associated with childhood malnutrition, and irritable bowel syndrome. Ranging from Phase 1 interventional studies to non-applicable or unspecified designs, these trials feature recruitment statuses of recruiting, completed, withdrawn, and unknown. Funding is provided by academic universities, research foundations, international agencies, and corporate sponsors such as GlaxoSmithKline.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06392360 | Recruiting | Metabolic Disturbance|Permeability; Increased |
Appalachian State University|AGRANA |
2024-05-13 | Not Applicable |
| NCT05999708 | Withdrawn | Colitis Ulcerative |
GlaxoSmithKline |
2023-10-31 | Phase 1 |
| NCT04109352 | Unknown status | Glucose-Galactose Malabsorption|Enteropathy|Malnutrition Child|Intestinal Permeability|Linear Growth Failure |
University of Virginia|International Atomic Energy Agency|Flinders University|International Centre for Diarrhoeal Disease Research Bangladesh|St. John''s Research Institute|The University of The West Indies|Mmust Masinde Muliro University of Science and Technology|Asociacion Benefica Prisma|Scottish Universities Environmental Research Centre|University of Michigan|Tropical Diseases Research Centre Zambia|Gastroenterology Services Ltd. |
2019-09-01 | -- |
| NCT03986476 | Completed | IBS |
Örebro University Sweden |
2019-03-26 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).